# Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer

> **NCT00640081** · PHASE2 · COMPLETED · sponsor: **Cheryl Pugh** · enrollment: 169 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** capecitabine
- **DRUG:** fluorouracil
- **DRUG:** leucovorin calcium
- **DRUG:** oxaliplatin
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00640081
- **Lead sponsor:** Cheryl Pugh
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-06
- **Final completion:** 2015-09
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2021-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00640081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00640081, "Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00640081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*